BRIEF-Infinity Pharma says new preclinical data show IPI-549 can reverse tumor resistance to checkpoint inhibitors

* Announced data for ipi-549, orally administered immuno-oncology development candidate that selectively inhibits pi3k-gamma
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.